Kazia Therapeutics
KZIA
22 hedge funds and large institutions have $17.1M invested in Kazia Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.
1,398% more capital invested
Capital invested by funds: $1.14M → $17.1M (+$15.9M)
1,100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 1
100% more funds holding
Funds holding: 11 → 22 (+11)
7.73% more ownership
Funds ownership: 14.14% → 21.87% (+7.7%)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$6.29M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$3.92M |
| 3 |
BL
Bleichroeder LP
New York
|
+$3.41M |
| 4 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$2.56M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
-$1.01M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$28.6K |
| 3 |
Citigroup
New York
|
-$5.44K |
| 4 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$375 |
| 5 |
Barclays
London,
United Kingdom
|
-$9 |
KZIA Hedge Fund Activity: Q4 2025 in Review
22 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q4 2025, worth a combined $17.1M — up 1,398% from $1.14M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KZIA positions and 1 closed out — a net gain of 11 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $6.29M. The largest seller was Dauntless Investment Group, cutting an estimated $1.01M.
- 22 institutional investors held Kazia Therapeutics (KZIA) as of Q4 2025, up from 11 in Q3 2025.
- Funds reported $17.1M of Kazia Therapeutics stock for Q4 2025, up 1,398% quarter-over-quarter.
- 12 funds opened new Kazia Therapeutics positions in Q4 2025 and 1 closed out, a net change of +11 holders.
- The largest Kazia Therapeutics buyer in Q4 2025 was Alyeska Investment Group, an estimated $6.29M added.
- The largest Kazia Therapeutics seller in Q4 2025 was Dauntless Investment Group, an estimated $1.01M sold.
Based on aggregated 13F filings for Q4 2025.